A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

Francis J. Giles, Jörge E. Cortes, Dan Jones et al. · Blood · 2006 · 361 citations · Full text

Medicine, Oncology, Pharmacology +12

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

Bob Löwenberg, Petra Muus, Gert J. Ossenkoppele et al. · Blood · 2011 · 121 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +10

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

Kevin R. Kelly, Jeffrey Ecsedy, Ernest Medina et al. · Journal of Cellular and Molecular Medicine · 2010 · 73 citations · Full text

Medicine, Oncology, Pharmacology +8

Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen

John McLaughlin, Vadim Markovtsov, Hui Li et al. · Journal of Cancer Research and Clinical Oncology · 2009 · 68 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +10

A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia

Kosuke Tsuboi, Toshiya Yokozawa, Toru Sakura et al. · Leukemia Research · 2011 · 55 citations

Medicine, Pharmacokinetics, Pharmacology +9